Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis

Seattle-based company Sana Biotechnology (Sana) received FDA clearance for its Investigational New Drug application aimed at treating “patients with multiple B-cell mediated autoimmune diseases,” according to a company press release.

The drug, SC291, is a cell therapy that operates by repurposing T cells from healthy donors to target B cells, which are known to contribute to the creation of autoimmune diseases in the body. SC291 is specifically designed for patients suffering from lupus (lupus nephritis and extrarenal lupus) and ANCA-associated vasculitis, a group of uncommon autoimmune diseases.

“Our goal is to develop SC291 for patients with multiple B-cell mediated autoimmune diseases, and the clearance of this IND is an important milestone,” said Doug Williams, PhD, Sana’s President of Research and Development. “SC291 is an allogeneic CAR T cell therapy with a scaled manufacturing process that produces hundreds of patient doses per manufacturing run, which we believe will be critical to addressing these large unmet needs.”

Photo credited to Sana Biotechnology.

READ THE STORY at The Wall Street Journal »